Journal of Glycobiology

Journal of Glycobiology
Open Access

ISSN: 2168-958X

+44 1478 350008

Cytoprotective properties of plant-produced a sialo erythropoietin (asialo-rhuEPO)


Glycobiology World Congress

August 10-12, 2015 Philadelphia, USA

Jiahua Jay Xie

Scientific Tracks Abstracts: J Glycobiol

Abstract :

Asialo-rhuEPO, a non-hematopoietic recombinant human erythropoietin (EPO) derivative lacking sialic acid has been
reported to display broad tissue-protective effects against damage triggered by ischemia/reperfusion, hypoxia or cytotoxic
agents in the brain, the heart, the kidneys and the liver. However, attempts to translate its protective effects into clinical practice
is hampered by unavailability of suitable expression system and its costly and limit production from expensive mammalian
cell-made EPO (rhuEPOM) by enzymatic desialylation. It is known that plants can synthesize complex N-glycans similar to
mammals but lack sialylating capacity. In our lab, we generated stable transgenic tobacco lines co-expressing human EPO
and β1,4-galactosyltransferase (GalT) genes to produce asialo-rhuEPO (asialo-rhuEPOP) lacking sialic acid but bearing
mammalian-type β1,4-galactose residues. We also developed an efficient purification system for isolating asialo-rhuEPOP from
leaf tissues both at small scale (grams) and medium scale (kilograms). Purified asialo-rhuEPOP from transgenic tobacco leaves
was found to have superior cytoprotective effect than rhuEPOM in protecting neuronal-like mouse neuroblastoma cells, murine
HL-1 cardiomyocytes and pancreatic β-cells from staurosporine-induced cell death. These milestone studies have set the stage
for the future investigations on its tissue-protective effects and action mechanisms in various animal models of tissue injury.

Biography :

Jiahua Jay Xie has completed his PhD in Biophysics at the age of 31 from Zhejiang University and Postdoctoral studies from Departments of Genetics and
Horticultural Science, North Carolina State University. He served as a Senior Scientist at the Vector Research Inc. (a subsidiary of Vector Group Ltd) for five years.
Currently, he is an Associate Professor in the Department of Pharmaceutical Sciences and the PI of the BRITE, NCCU. He has published more than 50 papers in
reputed journals and has been serving as an Editorial Board Member of Journal of Zhejiang University (Agriculture and Life Sciences).

Top